View in EDS

Zinc-Assisted Microscale Granules Made of the SARS-CoV-2 Spike Protein Trigger Neutralizing, Antivirus Antibody Responses

Saved in:
Bibliographic Details
Title: Zinc-Assisted Microscale Granules Made of the SARS-CoV-2 Spike Protein Trigger Neutralizing, Antivirus Antibody Responses
Authors: Marianna T. P. Favaro, Patricia Alamo, Nerea Roher, Miguel Chillon, Jara Lascorz, Merce Márquez, José Luis Corchero, Rosa Mendoza, Carlos Martínez-Torró, Neus Ferrer-Miralles, Luis C. S. Ferreira, Ramón Mangues, Esther Vázquez, Eloi Parladé, Antonio Villaverde
Contributors: Institut Català de la Salut, [Favaro MTP] Institut de Biotecnologia i de Biomedicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. Instituto de Ciências Biomédicas, Universidade de São Paulo, São Paulo, Brazil. [Alamo P] Institut de Recerca Sant Pau, Barcelona, (IR Sant Pau), Barcelona, Spain. Josep Carreras Leukaemia Research Institute (IJC), Badalona, Spain. CIBER de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN, ISCIII), Institut de Recerca Sant Pau, Barcelona, Spain. [Roher N] Institut de Biotecnologia i de Biomedicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. CIBER de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN, ISCIII), Institut de Recerca Sant Pau, Barcelona, Spain. Department of Cell Biology, Animal Physiology and Immunology, Universitat Autònoma de Barcelona, Bellaterra, Spain. [Chillon M] Department of Biochemistry and Molecular Biology, Institut de Neurociènces (INc), Universitat Autònoma de Barcelona, Bellaterra, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Unitat Producció de Vectors (UPV), Universitat Autònoma de Barcelona, Bellaterra, Spain. Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain. [Lascorz J] Institut de Biotecnologia i de Biomedicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. CIBER de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN, ISCIII), Institut de Recerca Sant Pau, Barcelona, Spain. [Márquez M] Institut de Biotecnologia i de Biomedicina, Universitat Autònoma de Barcelona, Bellaterra, Spain, Vall d'Hebron Barcelona Hospital Campus
Source: Scientia
Scientia. Dipòsit d'Informació Digital del Departament de Salut
instname
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
Publisher Information: American Chemical Society (ACS), 2024.
Publication Year: 2024
Subject Terms: TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapia biológica::inmunomodulación::inmunoterapia::inmunización::inmunoterapia activa::vacunación, Immunology, Vaccination, DISEASES::Bacterial Infections and Mycoses::Infection::Communicable Diseases, ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Biological Therapy::Immunomodulation::Immunotherapy::Immunization::Immunotherapy, Active::Vaccination, Peptides and proteins, 3. Good health, Biopolymers, COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas sanguíneas::inmunoproteínas::inmunoglobulinas::anticuerpos, CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Immunoproteins::Immunoglobulins::Antibodies, Malalties transmissibles, Vacunació, Antigens, Immunoglobulines, ENFERMEDADES::infecciones bacterianas y micosis::infección::enfermedades transmisibles
Description: The development of new and more efficient vaccination approaches is a constant need, due to the pressure of historical and emerging infectious diseases and the limited efficacy and universality of the current vaccination technologies. Peptides and recombinant proteins have been explored for decades as subunit vaccines for bacterial and viral infections, presented either as soluble protein species or as virus-like assemblies. Recently, synthetic secretory protein-only microscale granules have been developed as dynamic depots for sustained protein release. They are based on the reversible coordination between ionic Zn and histidine residues, which promotes a fast formation of granular particles in vitro out of soluble protein and a slow release of such building block protein in vivo through the physiological chelation of the metal. Such an endocrine-like platform represents a new drug delivery system fully validated in oncology by which soluble and functional protein drugs are progressively released from the granules and made available for antitumor activities upon subcutaneous administration. By exploring such an approach for immunization here, microparticles made of a recombinant form of the receptor binding domain (RBD) of SARS-CoV-2 were tested as an antigen delivery system for induction of antibody responses against the virus upon administration of the material in the absence of added adjuvants. Also, the comparison between protein materials produced in bacterial, mammalian, or insect cell factories has demonstrated a moderate impact of protein glycosylation on the final immunological performance of the system. Therefore, we propose the consideration of synthetic protein secretory granules as a new sustainable immunization platform based on fully manageable, self-organized, and self-formulated immunogens, aimed at reducing the dosage, costs, and complexity of vaccination regimens.
The authors appreciate the financial support received from AGAUR (2020PANDE00003 and 2021SGR00092 to A.V.), from CIBER-Consorcio Centro de Investigación Biomédica en Red- (CB06/01/0014), Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación, through intramural projects (NANOSARS to E.P. and NANOREMOTE to E.V.). We also appreciate the support from AEI for the development of multimeric recombinant drugs (PID2019-105416RB-I00/AEI/10.13039/501100011033 and PDC2022-133858-I00 to E.V., PID2019-107298RB-C22 to N.F.-M., PID2020-116174RB-I00 to A.V. and PID2022-1368450 OB-10/AEI/10.13039/501100011033 to A.V. and E.V.). M.T.P.F. received a FAPESP fellowship (No. 2021/08528-0) and L.C.S.F. received a FAPESP research grant (No. 2020/05204-7). A.V. received an ICREA ACADEMIA award.
Gránulos secretores de proteínas; SARS-CoV-2; Anticuerpos
Grànuls secretors de proteïnes; SARS-CoV-2; Anticossos
Protein secretory granules; SARS-CoV-2; Antibodies
Document Type: Article
File Description: application/pdf
Language: English
ISSN: 2639-4979
DOI: 10.1021/acsmaterialslett.3c01643
Access URL: https://hdl.handle.net/11351/11199
https://ddd.uab.cat/record/290133
Rights: CC BY
Accession Number: edsair.doi.dedup.....8cdd379c3b40ab06dfd1ffdaf0e6b5fe
Database: OpenAIRE
Description
Abstract:The development of new and more efficient vaccination approaches is a constant need, due to the pressure of historical and emerging infectious diseases and the limited efficacy and universality of the current vaccination technologies. Peptides and recombinant proteins have been explored for decades as subunit vaccines for bacterial and viral infections, presented either as soluble protein species or as virus-like assemblies. Recently, synthetic secretory protein-only microscale granules have been developed as dynamic depots for sustained protein release. They are based on the reversible coordination between ionic Zn and histidine residues, which promotes a fast formation of granular particles in vitro out of soluble protein and a slow release of such building block protein in vivo through the physiological chelation of the metal. Such an endocrine-like platform represents a new drug delivery system fully validated in oncology by which soluble and functional protein drugs are progressively released from the granules and made available for antitumor activities upon subcutaneous administration. By exploring such an approach for immunization here, microparticles made of a recombinant form of the receptor binding domain (RBD) of SARS-CoV-2 were tested as an antigen delivery system for induction of antibody responses against the virus upon administration of the material in the absence of added adjuvants. Also, the comparison between protein materials produced in bacterial, mammalian, or insect cell factories has demonstrated a moderate impact of protein glycosylation on the final immunological performance of the system. Therefore, we propose the consideration of synthetic protein secretory granules as a new sustainable immunization platform based on fully manageable, self-organized, and self-formulated immunogens, aimed at reducing the dosage, costs, and complexity of vaccination regimens.<br />The authors appreciate the financial support received from AGAUR (2020PANDE00003 and 2021SGR00092 to A.V.), from CIBER-Consorcio Centro de Investigación Biomédica en Red- (CB06/01/0014), Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación, through intramural projects (NANOSARS to E.P. and NANOREMOTE to E.V.). We also appreciate the support from AEI for the development of multimeric recombinant drugs (PID2019-105416RB-I00/AEI/10.13039/501100011033 and PDC2022-133858-I00 to E.V., PID2019-107298RB-C22 to N.F.-M., PID2020-116174RB-I00 to A.V. and PID2022-1368450 OB-10/AEI/10.13039/501100011033 to A.V. and E.V.). M.T.P.F. received a FAPESP fellowship (No. 2021/08528-0) and L.C.S.F. received a FAPESP research grant (No. 2020/05204-7). A.V. received an ICREA ACADEMIA award.<br />Gránulos secretores de proteínas; SARS-CoV-2; Anticuerpos<br />Grànuls secretors de proteïnes; SARS-CoV-2; Anticossos<br />Protein secretory granules; SARS-CoV-2; Antibodies
ISSN:26394979
DOI:10.1021/acsmaterialslett.3c01643